The Europe Cell-based Assays Market should witness market growth of 7.7% CAGR during the forecast period (2022-2028).
The facilitation and creation of complicated and physiologically relevant data are two examples of the benefits that can be gained from using cell-based assays. Cell-based assays, in contrast to more classic biochemical ones, are more physiologically essential and have the ability to examine compound properties simultaneously. Assays that measure cell viability or proliferation are both useful tools for determining whether or not a cell is healthy.
Dye assays, utilizing substances, like trypan blue or Calcein-AM, or readouts based on fluorescent light are frequently used to evaluate cellular viability and proliferation rate. These tests can be utilized to determine the number of mammalian cell lines, primary cells, and stem cells, as well as their overall state of health. The process of cell migration involves the movement of cells in response to certain external cues. These signals might be chemical or mechanical in nature.
During the process of cell invasion, cells have the ability to alter their surroundings as they move through the three-dimensional architecture of the extracellular matrix. In vitro evaluation of cell invasion and movement is possible using membrane-based migration methods, such as the Boyden Chamber test. These technologies are quite common and widely utilized. In cancer research, cell migration and invasion kits are frequently used to evaluate cell motility along with invasiveness in response to chemotactic gradients.
The production of new blood vessels from preexisting vasculature is referred to as angiogenesis. This process is governed by chemical signals. In in vitro cell models, angiogenesis can be induced or inhibited, and the assays for this process can be used to examine either of these processes. The creation of cell-based assays for the purpose of drug discovery helps speed up the optimization of therapeutics for cancer as well as other diseases that are dependent on angiogenesis.
The research and development industry in European countries is highly robust. According to the Organization for Economic Co-operation and Development Library, Europe consists of 21 OECD countries that are also members of the European Union, in addition to Iceland, Norway, and Switzerland. The government's funds for research and development, or GBARD, include both the R&D that is carried out directly by the government and the sums that are given to other institutions for R&D. Research and development (R&D) in the area of health pertains to GBARD's efforts to protect, promote, and restore human health, which encompasses all facets of medical and social care.
The Germany market dominated the Europe Cell-based Assays Market by Country in 2021; thereby, achieving a market value of $1.6 billion by 2028. The UK market is exhibiting a CAGR of 6.9% during (2022-2028). Additionally, The France market would experience a CAGR of 8.5% during (2022-2028).
Based on Application, the market is segmented into Drug Discovery, Basic Research and Others. Based on End-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes and Contract Research Organizations (CROs). Based on Products & Services, the market is segmented into Assay Kits, Reagents, Microplates, Probes & Labels, Instruments & Software and Cell Lines. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Corning Incorporated, Charles River Laboratories International, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Lonza Group AG, Merck Group, Promega Corporation and Thermo Fisher Scientific, Inc.
The facilitation and creation of complicated and physiologically relevant data are two examples of the benefits that can be gained from using cell-based assays. Cell-based assays, in contrast to more classic biochemical ones, are more physiologically essential and have the ability to examine compound properties simultaneously. Assays that measure cell viability or proliferation are both useful tools for determining whether or not a cell is healthy.
Dye assays, utilizing substances, like trypan blue or Calcein-AM, or readouts based on fluorescent light are frequently used to evaluate cellular viability and proliferation rate. These tests can be utilized to determine the number of mammalian cell lines, primary cells, and stem cells, as well as their overall state of health. The process of cell migration involves the movement of cells in response to certain external cues. These signals might be chemical or mechanical in nature.
During the process of cell invasion, cells have the ability to alter their surroundings as they move through the three-dimensional architecture of the extracellular matrix. In vitro evaluation of cell invasion and movement is possible using membrane-based migration methods, such as the Boyden Chamber test. These technologies are quite common and widely utilized. In cancer research, cell migration and invasion kits are frequently used to evaluate cell motility along with invasiveness in response to chemotactic gradients.
The production of new blood vessels from preexisting vasculature is referred to as angiogenesis. This process is governed by chemical signals. In in vitro cell models, angiogenesis can be induced or inhibited, and the assays for this process can be used to examine either of these processes. The creation of cell-based assays for the purpose of drug discovery helps speed up the optimization of therapeutics for cancer as well as other diseases that are dependent on angiogenesis.
The research and development industry in European countries is highly robust. According to the Organization for Economic Co-operation and Development Library, Europe consists of 21 OECD countries that are also members of the European Union, in addition to Iceland, Norway, and Switzerland. The government's funds for research and development, or GBARD, include both the R&D that is carried out directly by the government and the sums that are given to other institutions for R&D. Research and development (R&D) in the area of health pertains to GBARD's efforts to protect, promote, and restore human health, which encompasses all facets of medical and social care.
The Germany market dominated the Europe Cell-based Assays Market by Country in 2021; thereby, achieving a market value of $1.6 billion by 2028. The UK market is exhibiting a CAGR of 6.9% during (2022-2028). Additionally, The France market would experience a CAGR of 8.5% during (2022-2028).
Based on Application, the market is segmented into Drug Discovery, Basic Research and Others. Based on End-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes and Contract Research Organizations (CROs). Based on Products & Services, the market is segmented into Assay Kits, Reagents, Microplates, Probes & Labels, Instruments & Software and Cell Lines. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Corning Incorporated, Charles River Laboratories International, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Lonza Group AG, Merck Group, Promega Corporation and Thermo Fisher Scientific, Inc.
Scope of the Study
By Application
- Drug Discovery
- Basic Research
- Others
By End-user
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
By Products & Services
- Assay Kits
- Reagents
- Microplates
- Probes & Labels
- Instruments & Software
- Cell Lines
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Corning Incorporated
- Charles River Laboratories International, Inc.
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Lonza Group AG
- Merck Group
- Promega Corporation
- Thermo Fisher Scientific, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Europe Cell-based Assays Market by Application
Chapter 5. Europe Cell-based Assays Market by End-use
Chapter 6. Europe Cell-based Assays Market by Products & Services
Chapter 7. Europe Cell-based Assays Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Corning Incorporated
- Charles River Laboratories International, Inc.
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Lonza Group AG
- Merck Group
- Promega Corporation
- Thermo Fisher Scientific, Inc.
Methodology
LOADING...
